Hormonal
Tirzepatide (15 mg weekly) produces significantly greater weight loss than other market-available obesity medications, including semaglutide 2.4 mg, and achieves weight reduction comparable to bariatric surgery.
Tirzepatide is a highly effective, once-weekly injection for obesity that causes significantly more weight loss than other drugs like semaglutide and rivals bariatric surgery. However, it causes gastrointestinal side effects (nausea, diarrhea) which usually improve over time. It must be used alongside lifestyle changes because stopping the drug leads to rapid weight regain. Consult a doctor to manage side effects and determine if you are a candidate.
Research shows that tirzepatide at doses of 10 mg or 15 mg once a week provided significant and sustained weight reduction... It is more effective in weight reduction than other available market preparations used in the treatment of obesity... tirzepatide's effects are comparable to bariatric surgeries
Why this rating
Based on multiple Phase 3 randomized clinical trials (SURMOUNT-1, -2, -3, -4, SURPASS).
Source
Tirzepatide - A Revolution in Obesity Treatment?
Aleksandra Jaroń et al. · Quality in Sport · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →